title: Comparison of hepatocellular carcinoma with cirrhosis patients undergoing hepatic resection between hepatitis B and C infection.
abstract: OBJECTIVE
  Type B and C hepatic cirrhosis are main causes of hepatocellular carcinoma (HCC). In resected cases of HCC, residual liver function of type B cirrhotic patients tend to be better compared to type C cirrhotic patients. We compared clinical data of patients with type B hepatic cirrhosis with type C hepatic cirrhosis who underwent hepatic resection for HCC.
  
  
  METHODS
  Subjects were 16 patients with type B hepatic cirrhosis and 20 patients with type C hepatic cirrhosis who underwent hepatic resection for HCC at Jikei University Hospital. Perioperative findings including age, gender, preoperative laboratory data including ICGR15, Child's classification, model for end-stage liver disease (MELD) score, tumor factor, type of resection, duration of operation, blood loss and incidence of post-operative complications, as well as disease-free and overall survival were analyzed.
  
  
  RESULTS
  In type B cirrhotic patients, the age was younger (p<0.001), pre-operative ICGR15 (p=0.004), hemoglobin (p=0.032), albumin (p=0.006), Child's classification (p=0.008), and MELD score (p=0.011) were better, and incidence of postoperative pulmonary complications were fewer (p=0.039) than type C cirrhotic patients. Preoperative ICG, in 11 of 16 type B cirrhotic patients were normal (<10%).
  
  
  CONCLUSIONS
  Residual liver function of type B cirrhotic patients were better than type C cirrhotic patients.
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Shiba
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Ishida
authors.forename: Yuki
authors.initials: Y
authors.lastname: Fujiwara
authors.forename: Shigeki
authors.initials: S
authors.lastname: Wakiyama
authors.forename: Takeshi
authors.initials: T
authors.lastname: Gocho
authors.forename: Ryusuke
authors.initials: R
authors.lastname: Ito
authors.forename: Tomonori
authors.initials: T
authors.lastname: lida
authors.forename: Fumitake
authors.initials: F
authors.lastname: Suzuki
authors.forename: Kenei
authors.initials: K
authors.lastname: Furukawa
authors.forename: Koichiro
authors.initials: K
authors.lastname: Haruki
authors.forename: Takeyuki
authors.initials: T
authors.lastname: Misawa
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Yanaga
mesh_terms: D000367:Age Factors; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000175:diagnosis / Q000401:mortality / Q000601:surgery* / Q000821:virology; D016009:Chi-Square Distribution; D018572:Disease-Free Survival; D005260:Female; D006498:Hepatectomy / Q000009:adverse effects / Q000401:mortality; D006509:Hepatitis B / Q000097:blood / Q000150:complications* / Q000175:diagnosis / Q000401:mortality; D006526:Hepatitis C / Q000097:blood / Q000150:complications* / Q000175:diagnosis / Q000401:mortality; D006785:Hospitals, University; D006801:Humans; D007564:Japan; D008103:Liver Cirrhosis / Q000097:blood / Q000175:diagnosis / Q000401:mortality / Q000601:surgery* / Q000821:virology; D008111:Liver Function Tests; D008113:Liver Neoplasms / Q000097:blood / Q000175:diagnosis / Q000401:mortality / Q000601:surgery* / Q000821:virology; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D012307:Risk Factors; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor